思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1244)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of 3D Medicines Inc. (the "**Company**" together with its subsidiaries, the "**Group**") announces the following changes of directors ("**Director(s)**") of the Company:

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Zhu Jinqiao ("**Mr. Zhu**") will retire as non-executive Director on August 7, 2026, as he wishes to devote more time to pursue his other work engagements.

Mr. Zhu confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholder(s)**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude to Mr. Zhu for his valuable contributions during his tenure of office as a non-executive Director.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is delighted to announce that following Mr. Zhu's retirement, the Board appointed Ms. Zhang Wenhua as a non-executive Director with effect from August 7, 2026.

Ms. Zhang Wenhua ("**Ms. Zhang**"), aged 39, has over 15 years of experience in finance, investment and fund operation and management. Since July 2026 to the present, Ms. Zhang has served as Managing Director at Efung Investment Management Limited Partnership Enterprise (L.P.) (深圳市倚鋒投資管理企業(有限合夥)) ("**Efung Capital**"). From September 2017 to June 2026, Ms. Zhang served in the financial segment of China International Marine Containers (Group) Co., Ltd. ("**CIMC Group**"). During this period, she successively held the positions of Director of Operations of CIMC Assets Capital Management Co., Ltd. and Director of Risk Control of Mangrove Capital Management Ltd. From July 2015 to August 2017, she served as Senior Manager of the Corporate Client Department at BOC International Securities Co., Ltd. From July 2009 to April 2013, she served as Audit Specialist and General Manager Assistant at Shenzhen Hongxin Certified Public Accountants Firm.

Ms. Zhang pursued her studies at the University of Hull, United Kingdom from July 2013 to July 2014 and obtained a Master's degree in Finance and Investment. She studied at Shenzhen University from September 2005 to June 2009 and was awarded a Bachelor's degree in Management.

Ms. Zhang has entered into a letter of appointment with the Company. Her directorship in the Company shall be for a term of one year commencing from August 7, 2026. Ms. Zhang's directorship is subject to the retirement by rotation and re-election at an annual general meeting of the Company (the "**AGM**") in accordance with the provision of the Articles of Association (the "**Articles**") and the Listing Rules. Ms. Zhang will hold the office until the next following AGM and will retire at that AGM, but will be eligible for re-election in accordance with the Articles. Ms. Zhang will not receive directors' fee from the Company for her service as the non executive Director nor will she receive any remuneration from any member of the Group. Her remuneration as a non-executive Director will be reviewed from time to time at the discretion of the Board by reference to her duties and responsibilities with the Company, the Company's business performance, profitability and prevailing market conditions and to be authorised by the shareholders of the Company at the AGM.

As at the date of this announcement, Ms. Zhang does not have any interests in the shares (the "**Shares**"), underlying Shares and debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "**SFO**").

As at the date of this announcement and save as disclosed above, Ms. Zhang confirms that she did not have any relationship with any director, senior management, chief executive or substantial shareholder or controlling shareholder of the Company and hold no other position within the Group. Within the meaning of Part XV of the Securities and Futures Ordinance, Ms. Zhang also confirms that she does not have any interest in the shares or underlying shares of the Company and she has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years and she does not have any major appointments and professional qualifications. There is no other matter that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any of the requirements of rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

By Order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board and Executive Director

Hong Kong, August 7, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.